Clinical roundtable monograph: New data in emerging treatment options for chemotherapy-induced nausea and vomiting.

Academic Article

Abstract

  • Chemotherapy-induced nausea and vomiting (CINV) has long been one of the most troublesome adverse effects of chemotherapy, leading to significant detriments in quality of life and functioning, increased economic costs, and, in some cases, the discontinuation of effective cancer therapy. The past 2 decades have witnessed a dramatic increase in the number of effective antiemetic agents, with the introduction of the serotonin (5-hydroxytryptamine [5-HT₃]) receptor antagonists (ondansetron, granisetron, and palonosetron), the neurokinin-1 (NK₁) receptor antagonists (aprepitant and fosaprepitant), and the identification of other agents that have demonstrated efficacy against CINV, including corticosteroids. These agents often provide excellent control of emesis. Nausea, however, has proven more intractable, particularly in the days after administration of chemotherapy. Newer antiemetic agents under study may provide additional CINV control, particularly against delayed nausea. New agents undergoing review by the US Food and Drug Administration for the prevention of CINV include the novel NK₁ receptor antagonist rolapitant and a fixed-dose combination consisting of the novel NK₁ receptor antagonist netupitant and palonosetron (NEPA). Adherence to clinical practice guidelines has been shown to significantly improve CINV control. As antiemetic therapy continues to evolve, it will be important for clinicians to stay informed of new developments and changes in guidelines.
  • Keywords

  • Antiemetics, Antineoplastic Agents, Humans, Nausea, Neoplasms, Practice Guidelines as Topic, Quality of Life, United States, United States Food and Drug Administration, Vomiting
  • Author List

  • Morrow GR; Navari RM; Rugo HS
  • Start Page

  • 1
  • End Page

  • 14
  • Volume

  • 12
  • Issue

  • 3 Suppl 9